Regen Med. 2015;10(7):841-55. doi: 10.2217/rme.15.49. Epub 2015 Nov 6.

A comparison of Wharton's jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.

El-Demerdash RF¹, Hammad LN¹, Kamal MM², El Mesallamy HO².

Abstract

AIM:

In this study, we investigated the differences between mesenchymal stem cells (MSCs), isolated from umbilical cord blood (UCB-MSCs) and Wharton's jelly (WJ-MSCs) as sources of diabetes mellitus cell therapy.

METHODS:

After isolation, both cell types were induced to differentiate into insulin producing cells, then the differentiated cells were assessed genetically and functionally. UCB-MSCs and WJ-MSCs were transplanted in the tail veins of streptozotocin-induced diabetic rats. Blood glucose levels were monitored post-transplantation.

RESULTS & CONCLUSION:

Wharton's jelly was more homogeneous, can better differentiate into insulin producing cells in vitro and better control hyperglycemia in diabetic rats in vivo, as compared with UCB. These results indicate that WJ-MSCs represent a potential source of cells in the field of diabetes mellitus cell therapy.